P/86/2010 - paediatric investigation plan

cediranib maleate

Key facts

• Active Substance:
  cediranib maleate
• Therapeutic area:
  Oncology
• Decision number:
  P/86/2010
• PIP number:
  P/86/2010
• Pharmaceutical form(s):
  Tablet
• Condition(s) / indication(s):
  Treatment of high-grade glioma
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  AstraZeneca AB (UK)

  Tel. [phone]; E-mail: [e-mail]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  01/06/2010

Decision

P/86/2010: European Medicines Agency decision of 1 June 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for cediranib maleate (EMEA-000477-PIP01-0...

AdoptedReference Number: EMA/330478/2010